Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

Diabetes Care

Volumn 23, Issue 4, 2000, Pages 518-523

  Owens, David R ^a   Luzio, Stephen D ^a   Ismail, Ikram ^a   Bayer, Thomas ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 0034069665     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.4.518     Document Type: Article

References (28)

1. Yki-Järvinen H: Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343:91-95, 1994
2. Zimmet P. Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid carboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11: 299-303, 1994
3. Beck-Nielsen H, Hother-Nielsen O, Pedersen O: Mechanism of action oi sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 5:613-620, 1988
4. Owens DR, Luzio SD, Coates PA: Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the U.K. Diabet Med 13:S19-S24, 1996
5. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967. 1994
6. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
7. Turner RC, Millns H, Neil HA, Strattom IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998
8. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
9. Laaskso M, Lehto S: Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 137 (Suppl.):S65-S73, 1998
10. Colwell JA, Lein A: Diminished insulin response to hyperglycemia in prediabetes and diabetes. Diabetes 16:560-565, 1967
11. Kosaka K. Hagura R, Kuzuya T: Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 26: 944-952, 1977
12. Yoneda H, Ikegami H, Yamamoto Y, Yamato E, Cha T, Kawaguchi Y, Tahara Y, Ogihara T: Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care 15:1517-1521, 1992
13. Mitrakou A, Kelley D, Mokan M, Veneman T, Reilly J, Gench J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29, 1992
14. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M: Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest 101:86-96, 1998
15. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37:736-744, 1988
16. Luzio SD, Owens DR, Vora J, Dolben J, Smith H: Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Res 16:63-67, 1991
17. Dunning E: New non-sulfonylurea insulin secretagogues. Exp Opin Invest Drugs 6:1-7, 1997
18. Ashcroft FM, Rorsman P: Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 54:87-143, 1989
19. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351, 1998
20. Viñambres C, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ: Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol Res 34:83-85, 1996
21. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8:260-266, 1972
22. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
23. Hovorka R, Soons PA, Young MA: ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264, 1996
24. Leahy JL: Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13:992-1010, 1990
25. Oliver S, Ahmad S, Windfeld K, Hatorp V: Pharmacokinetics and bioavailability of repaglinide: a new OHA for patients with NIDDM (Abstract). Diabetologia 40 (Suppl. 1): A320, 1997
26. Owens DR: Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs Diabet Med 15 (Suppl. 4):S28-S36, 1998
27. Damsbo P, Andersen PH, Lund S, Pørksen N: Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing (Abstract). Diabetes 46 (Suppl 1):A34, 1997
28. Ceriello A: The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 15:188-193, 1998